{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-035942","form_type":"8-K","ticker":"ADGM","cik":"0002006986","company_name":"Adagio Medical Holdings, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.348670+00:00","generated_at":"2026-05-31T12:42:39.757995+00:00","sec_items":["1.01","2.01","3.02","9.01","3.03","5.03","5.01","5.02","5.05","5.06","7.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Adagio Medical completes de-SPAC merger with ARYA, begins trading as ADGM on Nasdaq","bullets":["Post-combination, 13,387,636 shares of New Adagio common stock outstanding; 7,587 shares under options.","PIPE financing of ~$64.5M closed; $20M in 13% senior secured convertible notes issued with 1,500,000 warrants exercisable at $24/share.","Sponsor forfeited 1,000,000 Class B shares; additional 1,147,500 shares subject to vesting if stock reaches $24 for 20 trading days.","Shareholders redeemed 2,707,555 shares for ~$31.3M at ~$11.56 per share prior to closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-035942","json":"https://secwatch.observer/filing/0001140361-24-035942.json","markdown":"https://secwatch.observer/filing/0001140361-24-035942.md","text":"https://secwatch.observer/filing/0001140361-24-035942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/0001140361-24-035942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:42:39.757995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19a73b1ffb","claim":"Hakon Bergheim was appointed as Chief Operating Officer at Adagio Medical Holdings, Inc..","evidence_excerpt":"Hakon Bergheim 42 Chief Operating Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/0001140361-24-035942-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"4f348b6e7f","claim":"Olav Bergheim was appointed as Chief Executive Officer and Chairman at Adagio Medical Holdings, Inc..","evidence_excerpt":"Olav Bergheim 74 Chief Executive Officer and Chairman","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/0001140361-24-035942-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and Chairman"}],"fact_type":"executive_change"},{"claim_id":"64491743fe","claim":"James L. Cox was appointed as Class I Director at Adagio Medical Holdings, Inc..","evidence_excerpt":"Olav Bergheim and James L. Cox were appointed as Class I directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/0001140361-24-035942-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"786c38be2b","claim":"Keyvan Mirsaeedi-Farahani was appointed as Class III Director at Adagio Medical Holdings, Inc..","evidence_excerpt":"Keyvan Mirsaeedi-Farahani, Timothy Moran and Sandra Gardiner were appointed as Class III directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/0001140361-24-035942-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"8915c09aba","claim":"Orly Mishan was appointed as Class II Director at Adagio Medical Holdings, Inc..","evidence_excerpt":"Orly Mishan and Shahram Moaddeb were appointed as Class II directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/0001140361-24-035942-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"891e7d5ff4","claim":"Olav Bergheim was appointed as Class I Director at Adagio Medical Holdings, Inc..","evidence_excerpt":"Olav Bergheim and James L. Cox were appointed as Class I directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/0001140361-24-035942-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"aa731ef9f9","claim":"Shahram Moaddeb was appointed as Class II Director at Adagio Medical Holdings, Inc..","evidence_excerpt":"Orly Mishan and Shahram Moaddeb were appointed as Class II directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/0001140361-24-035942-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"b4072ccfb7","claim":"Timothy Moran was appointed as Class III Director at Adagio Medical Holdings, Inc..","evidence_excerpt":"Keyvan Mirsaeedi-Farahani, Timothy Moran and Sandra Gardiner were appointed as Class III directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/0001140361-24-035942-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"e1b2fe5872","claim":"John Dahldorf was appointed as Chief Financial Officer at Adagio Medical Holdings, Inc..","evidence_excerpt":"John Dahldorf 68 Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/0001140361-24-035942-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"fe89432e31","claim":"Sandra Gardiner was appointed as Class III Director at Adagio Medical Holdings, Inc..","evidence_excerpt":"Keyvan Mirsaeedi-Farahani, Timothy Moran and Sandra Gardiner were appointed as Class III directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/0001140361-24-035942-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"f3c6ca2e2aa7f6e8df515c22cfad40b88dd4a63a","claim":"Adagio Medical Holdings, Inc. underwent a change of control involving ARYA Sciences Acquisition Corp IV for exchange of shares of Adagio Common Stock for shares of New Adagio Common Stock based on the exchange ratio set forth in the Business Combination Agreement (closed 2024-07-31).","evidence_excerpt":"consummated the previously announced business combination (the \"Business Combination\") pursuant to the terms of the Business Combination Agreement","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/0001140361-24-035942-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"ARYA Sciences Acquisition Corp IV"},{"label":"Consideration","value":"exchange of shares of Adagio Common Stock for shares of New Adagio Common Stock based on the exchange ratio set forth in the Business Combination Agreement"},{"label":"Closing","value":"2024-07-31"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}